41 reports

  • SEGMENTATION OF TYPE 1 DIABETES DRUGS MARKET BY DRUG CLASS
  • GLOBAL TYPE 1 DIABETES DRUGS MARKET BY GEOGRAPHY 2015-2020

About Type 1 Diabetes Drugs Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types: - Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading...

  • Type 1 Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

Global Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Forecast

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Market Shares
  • Market Size
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 11.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS

PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

Europe Type ## Diabetes Epidemiology and Patient Flow Analysis - 2017 ##.

  • Type 1 Diabetes
  • Europe
  • France
  • Germany
  • Forecast
  • Prevalence of Type 1 Diabetes Mellitus, females (000s)
  • Prevalence of Type 1 Diabetes Mellitus, total (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Type 1 Diabetes Mellitus in 12 Major Markets Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas’ ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to...

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes

Type ## Diabetes (T##D) Market Size, Forecast And Trend Analysis, 2014 - 2024 Chapter ##.

  • Insulin
  • Therapy
  • Type 1 Diabetes
  • United States
  • Forecast
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS

Type 1 Diabetes - US Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS

Type 1 Diabetes - Japan Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014

Type 1 Diabetes - Canada Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group
  • LEADING TREATMENTS FOR TYPE 1 DIABETES, 2014
  • 9.4.1 DIAGNOSED TYPE 1 DIABETES PATIENTS

Type 1 Diabetes - 5EU Drug Forecast and Market Analysis to 2023 Summary Type 1 diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Over the last 90 years, insulin therapy has been evolving continuously, as at present,...

  • Type 1 Diabetes
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Chronic Disease
  • Pathology
  • Type 1 Diabetes
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • Japan
  • Demand
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • United States
  • Demand
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • United Kingdom
  • Demand
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • Italy
  • Demand
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • France
  • Demand
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • Germany
  • Demand
  • Market Shares
  • Market Size

Type ## Diabetes Phase ## Clinical Trials, 2016 ##.

  • Type 1 Diabetes
  • Spain
  • Demand
  • Market Shares
  • Market Size
  • 5.4.1 Diagnosed Type 1 Diabetes Patients
  • SALES FOR TYPE 1 DIABETES IN CANADA BY DRUG CLASS, 2013-2023

Type 1 Diabetes - Current and Future Players Summary GlobalData has released its pharma report, “Type 1 Diabetes - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Insomnia Market. The report identifies and analyses the key...

  • Type 1 Diabetes
  • Canada
  • North America
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • North America Insulin Pumps Market, By Value
  • L: EUROPE REGIONAL MARKERS: HISTORIC AND FORECAST

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Insulin Pumps Market By Region (North America, Europe, APAC, MEA and ROW) and By Country (U.S., Canada, Germany,...

  • Insulin Delivery
  • Type 1 Diabetes
  • World
  • Market Size
  • Animas Corporation

Drug analysis: Farxiga

9091 10000 7727

Drug analysis: Farxiga PRODUCT PROFILES Farxiga : Diabetes type ## Farxiga : Diabetes type ## LIST OF FIGURES Figure ##: Farxiga for type ## diabetes – SWOT analysis Figure ##: Datamonitor Healthcare drug assessment of Farxiga Figure ##: Datamonitor Healthcare drug assessment scorecard

  • Diabetes
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 1 Diabetes
  • European Union
  • United States
  • TYPE 1 DIABETES (JUVENILE DIABETES)
  • VACCINE FOR TYPE 1 DIABETES - DRUG PROFILE

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape. Type...

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company
  • Type 1 Diabetes (Juvenile Diabetes) - Overview
  • TYPE 1 DIABETES (JUVENILE DIABETES)

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape. Type...

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • World
  • Company

Type ## Diabetes Pipeline Highlights – 2017 ##.

  • Chronic Disease
  • Type 1 Diabetes
  • United States
  • Product Initiative

Type-## diabetes (Juvenile Diabetes) - Pipeline Review, H## 2015 Table of Contents Table of Contents ## Introduction ## Type-## diabetes (Juvenile Diabetes) Overview ## Therapeutics Development ## Type-## diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies

  • Chronic Disease
  • Diabetes
  • Pathology
  • Type 1 Diabetes
  • Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes - Drug Profile
  • Indication

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Pipeline Review, H1 2017 Summary According to the recently published report 'Aryl Hydrocarbon Receptor - Pipeline Review, H1 2017'; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target...

  • Hepatitis
  • Type 1 Diabetes
  • World
  • Product Initiative
  • Shenogen Pharma Group
  • Type 1 Diabetes
  • Inflammatory Bowel disease Type 1 Diabetes Thyroid Others

Autoimmune Disease Diagnostics Market The global autoimmune disease diagnostics market is expected to reach USD XXmillion by 2022 from USD XXmillion in 2016. During this period, the CAGR is expected to reach around XX%. There is an increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies coupled with...

  • Immunochemistry Test
  • Type 1 Diabetes
  • World
  • Market Size
  • Thermo Fisher Scientific, Inc.
  • JUN 28, 2010: TOLERX INITIATES CONFIRMATORY PHASE III TRIAL WITH OTELIXIZUMAB FOR TYPE 1 DIABETES
  • PIPELINE BY MACROGENICS INC, H2 2017

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017 Summary According to the recently published report ’T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017’; T Cell...

  • Therapy
  • Type 1 Diabetes
  • United States
  • World
  • Product Initiative
  • 05/22/2017: JDRF AND VIACYTE ANNOUNCE SUPPORT FOR DEVELOPMENT OF PEC-DIRECT CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES
  • 05/22/2017: JDRF AND VIACYTE ANNOUNCE SUPPORT FOR DEVELOPMENT OF PEC-DIRECT CELL REPLACEMENT THERAPY FOR TYPE 1 DIABETES

Summary ViaCyte Inc (ViaCyte), formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline product portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing...

  • Type 1 Diabetes
  • United States
  • Company
  • Product Initiative
  • ViaCyte, Inc.